Has John Khuu, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,664 in general payments to John Khuu, MD across 120 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean John Khuu, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about John Khuu, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

John Khuu, MD

Hematology & Oncology · Norton, VANPI 1063639011

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.5% of the total across 120 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 11.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $1,164 and has fallen 81.7% since, to $213 in 2025.

$2,664in general payments, 2019–2025

Across 120 payments — averaging $22.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$292
Merck$272
E.r. Squibb & Sons, L.L.C.$240
Johnson & Johnson$171
AstraZeneca$150
Novo Nordisk$123
plus $1K from 33 others

What the payments were for

Food & beverage$2,64999%
Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen	12	$292
Merck	13	$272
E.r. Squibb & Sons, L.L.C.	9	$240
Johnson & Johnson	7	$171
AstraZeneca	7	$150
Novo Nordisk	1	$123
Seagen Inc.	6	$117
Novartis	6	$108
Bristol Myers Squibb	4	$97
Incyte Corporation	4	$87
Pharmacyclics LLC, An Abbvie Company	4	$71
Pfizer	5	$69
Tersera Therapeutics LLC	2	$69
Takeda Pharmaceuticals U.S.A., Inc.	4	$54
Lilly USA, LLC	3	$46
Jazz Pharmaceuticals Inc.	1	$46
Gilead	2	$45
Bayer	2	$45
Beigene USA, Inc.	2	$42
Caris MPI, Inc.	2	$42
Puma Biotechnology, Inc.	2	$41
Daiichi Sankyo Inc.	2	$40
Eisai Inc.	2	$36
Sanofi	2	$35
Regeneron Healthcare Solutions, Inc.	1	$33
Foundation Medicine, Inc.	2	$33
EMD Serono, Inc.	1	$29
GSK	1	$29
AbbVie	1	$23
Genentech USA, Inc.	1	$22
Astellas Pharma US Inc	1	$22
Epizyme, Inc.	1	$22
Boehringer Ingelheim	1	$21
Blueprint Medicines Corporation	1	$19
Agios Pharmaceuticals, Inc.	1	$17
EUSA Pharma (US) LLC	1	$17
Rigel Pharmaceuticals, Inc.	1	$14
Exelixis Inc.	1	$13
Taiho Oncology, Inc.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Wegovy$123
EMPLICITI$110

How this compares

$2,664 in reported general payments places this provider in the 60th percentile of 293 hematology & oncology providers in Virginia.

See all hematology & oncology providers in Virginia →

Medicare billing

Part B allowed, 2024

$9,300

Medicare patients

Services billed

378

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Norton

Ruby KochharHampton$236K
Victor YazbeckRichmond$190K
David ChangNewport News$141K
William ErshlerFairfax$139K
Yue ZhangVirginia Beach$105K
Jerome GoldschmidtChristiansburg$105K
Attique SamdaniRichmond$104K
Gary SimmonsNorfolk$82K
Mark FlemingHampton$71K
Sekwon JangFairfax$56K

See the full list for Virginia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →